Found: 8
Select item for more details and to access through your institution.
Phase II Study With Epirubicin, Cisplatin, and Infusional Fluorouracil Followed by Weekly Paclitaxel With Metronomic Cyclophosphamide as a Preoperative Treatment of Triple-Negative Breast Cancer.
- Published in:
- Clinical Breast Cancer, 2015, v. 15, n. 4, p. 259, doi. 10.1016/j.clbc.2015.03.002
- By:
- Publication type:
- Article
Prevalence and Clinicopathologic Correlates of O<sup>6</sup>-Methylguanine-DNA Methyltransferase Methylation Status in Patients With Triple-Negative Breast Cancer Treated Preoperatively by Alkylating Drugs.
- Published in:
- Clinical Breast Cancer, 2014, v. 14, n. 4, p. 285, doi. 10.1016/j.clbc.2014.02.010
- By:
- Publication type:
- Article
Prevalence and Clinicopathologic Correlates of O(6)-Methylguanine-DNA Methyltransferase Methylation Status in Patients With Triple-Negative Breast Cancer Treated Preoperatively by Alkylating Drugs.
- Published in:
- 2014
- By:
- Publication type:
- Journal Article
Correction to: RE‑MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola‑BR), CAR‑T therapies, and lenalidomide/rituximab (R2) based on real‑world data in patients with relapsed/refractory diffuse large B‑cell lymphoma
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma
- Published in:
- Annals of Hematology, 2023, v. 102, n. 7, p. 1773, doi. 10.1007/s00277-023-05196-4
- By:
- Publication type:
- Article
Prognostic relevance of peritumoral vascular invasion in immunohistochemically defined subtypes of node-positive breast cancer.
- Published in:
- Breast Cancer Research & Treatment, 2014, v. 146, n. 3, p. 573, doi. 10.1007/s10549-014-3043-2
- By:
- Publication type:
- Article
ABCL-021: FRONT-MIND: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Comparing Efficacy and Safety of Tafasitamab + Lenalidomide + R-CHOP vs R-CHOP Alone for Newly-Diagnosed High-Intermediate and High-Risk Diffuse Large B-Cell Lymphoma (DLBCL)
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S376, doi. 10.1016/S2152-2650(21)01860-7
- By:
- Publication type:
- Article
Poster: ABCL-021: FRONT-MIND: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Comparing Efficacy and Safety of Tafasitamab + Lenalidomide + R-CHOP vs R-CHOP Alone for Newly-Diagnosed High-Intermediate and High-Risk Diffuse Large B-Cell Lymphoma (DLBCL)
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S244, doi. 10.1016/S2152-2650(21)01533-0
- By:
- Publication type:
- Article